Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Ligand Pharmaceuticals Incorporated (NASDAQ: LGND).

Full DD Report for LGND

You must become a subscriber to view this report.

Recent News from (NASDAQ: LGND)

Today's Research Reports on Trending Tickers: OPKO Health and Ligand Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / May 17, 2018 / U.S. markets closed up on Wednesday, as investors appear to shrug off fears of increasing interest rate and bond yields. The Dow Jones Industrial Average gained 0.25 percent to close at 24,768.93, while the S&P 500 Index increased 0.41 percent ...
Date: May, 17 2018 08:00
Ligand Announces Proposed Offering of $650 Million of Convertible Senior Notes
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it intends to offer, subject to market conditions and other factors, $650 million aggregate principal amount of convertible senior notes due 2023 in a private offering to qualified institutional buyers pursuant to Rule...
Source: Business Wire
Date: May, 16 2018 16:51
New Research Coverage Highlights Assurant, Williams Partners, Atmos Energy, Nationstar Mortgage, Applied Materials, and Ligand Pharmaceuticals - Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, May 15, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Assurant, Inc. (NYSE:AIZ), Williams Partners L.P. (NYSE:WPZ), Atmos Energy...
Source: GlobeNewswire
Date: May, 15 2018 07:35
Ligand to Participate in Upcoming Investor Conferences
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that company executives are scheduled to participate in the following upcoming investor conferences: • Berenberg Conference USA in Tarrytown, New York. Presentation takes place on Thursday, May 24, 2018 at 11:45 a.m. E...
Source: Business Wire
Date: May, 11 2018 09:00
Ligand Pharmaceuticals' (LGND) CEO John Higgins on Q1 2018 Results - Earnings Call
Ligand Pharmaceuticals, Inc. (LGND) Q1 2018 Earnings Conference Call May 8, 2018 4:30 PM ET Executives Todd Pettingill – Director-Corporate Development and Investor Relations John Higgins – Chief Executive Officer Matt Foehr – Chief Operating Officer Matt K...
Source: SeekingAlpha
Date: May, 08 2018 22:59
Ligand Pharmaceuticals beats by $0.40, beats on revenue
Ligand Pharmaceuticals (NASDAQ: LGND ): Q1 EPS of $1.55 beats by $0.40 . More news on: Ligand Pharmaceuticals Incorporated, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 08 2018 16:07
Ligand Reports First Quarter 2018 Financial Results
Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2018, and provided an operating forecast and program updates. Ligand management will host a conference call...
Source: Business Wire
Date: May, 08 2018 16:01
Ligand Pharma, iRhythm Tech new shorts at Lakeland Capital
Anthony Bozza sees more than  50% downside  in Ligand Pharmaceuticals ( LGND -3.1% ), according to his fund's Q1 letter. The market, he says, overvalues the company's pipeline. More news on: Ligand Pharmaceuticals Incorporated, iRhythm Technologies, Quick stock ideas, Tech stoc...
Source: SeekingAlpha
Date: April, 24 2018 14:34
Ligand to Report First Quarter 2018 Results on May 8th
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report first quarter 2018 financial results on May 8, 2018. Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call. Fir...
Source: Business Wire
Date: April, 24 2018 09:00
Ligand's Market Valuation Does Not Withstand Scrutiny
Ligand Pharmaceuticals ( LGND ) is a pharmaceutical patent licensor. In essence, it acquires pharma-related IP, such as its patented Captisol and OmniAb technologies, and licenses said IP to other pharma companies that are conducting drug research. In return, LGND receives royalties, license...
Source: SeekingAlpha
Date: April, 04 2018 12:42


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on LGND.

About Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)

Logo for Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)

Ligand discovers, develops and markets new drugs for critical unmet medical needs in the areas of cancer, pain, skin diseases, hormone related diseases, osteoporosis, metabolic disorders, cardiovascular and inflammatory diseases. Ligand s proprietary drug discovery and development programs are based on its leadership position in gene transcription technology related to intracellular receptors.


Contact Information



Current Management

  • David A. Robinson / President, CEO
  • Matthew A. Foehr / President, COO
  • John Higgins / President, CEO
    • Mr. Higgins served as Chief Financial Officer and Executive Vice President, Finance and Administration and Corporate Development, of Connetics Corporation, a specialty pharmaceutical company acquired by Stiefel Laboratories in . Before joining Connetics, he was a member of the executive management team at BioCryst Pharmaceuticals. Currently, he is a Director on the Boards of Techne Corporation, CoMentis and BioCryst and serves as Chairperson of the Techne Audit Committee. Prior to BioCryst, Mr. Higgins was a member of the healthcare banking team of Dillon, Read amp Co. Inc., an investment banking firm. He graduated Magna Cum Laude from Colgate University with an AB in economics.
  • Nishan de Silva / CFO
  • Matthew Korenberg / CFO, VP, Fin., Principal Acct. Officer
    • Mr. Korenberg has more than eighteen years of healthcare business experience across healthcare investing banking and operations. Prior to joining Ligand, commencing in September , Mr. Korenberg was the founder, Chief Executive Officer and a director of NeuroCircuit Therapeutics, a company focused on developing drugs to treat genetic disorders of the brain with an initial focus on Down syndrome. Prior to founding NeuroCircuit Therapeutics, Mr. Korenberg was a Managing Director and member of the healthcare investment banking team at Goldman Sachs from July through August . During his fourteen year tenure at Goldman Sachs, Mr. Korenberg was focused on advising and financing companies in the biotechnology and pharmaceutical sectors and was based in New York, London and San Francisco. Prior to Goldman Sachs, Mr. Korenberg was a healthcare investment banker at Dillon, Read amp Co. Inc. where he spent two years working with healthcare companies in the biotechnology and pharmaceutical sectors and industrial companies. Mr. Korenberg holds a B.B.A. in Finance and Accounting from The University of Michigan.
  • Charles A. Berkman / Vice President, Secretary, General Counsel
  • Erika Luib / IR
  • David A. Robinson / Chairman
  • Dr. Nancy Ryan Gray / Director
    • Dr. Gray, , has acted as the President and CEO of Gordon Research Conferences, a nonprofit organization focused on organizing international scientific conferences, since . From December until August she served as the Director of Membership for the American Chemical Society. Prior to that, Dr. Gray worked as a Senior Research Scientist at Exxon/Mobil Research and Engineering, a subsidiary of Exxon Mobil Corporation focused on researching oil and gas. Dr. Gray received her B.S. in Chemistry from the University of Notre Dame in and her Ph.D. in Fuel Science from The Pennsylvania State University in .
  • John LaMattina /
  • Sunil Patel /

Current Share Structure


    Recent Filings from (NASDAQ: LGND)

    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: May, 10 2018
    Quarterly report with a continuing view of a company's financial position
    Filing Type: 10-QFiling Source: edgar
    Filing Date: May, 09 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: May, 08 2018
    Official notification to shareholders of matters to be brought to a vote (Proxy)
    Filing Type: DEF 14AFiling Source: edgar
    Filing Date: April, 30 2018
    Additional proxy soliciting materials - definitive
    Filing Type: DEFA14AFiling Source: edgar
    Filing Date: April, 30 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: April, 13 2018
    Filing Type: CT ORDERFiling Source: edgar
    Filing Date: April, 03 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: March, 22 2018
    Amendment to a previously filed 8-K
    Filing Type: 8-K/AFiling Source: edgar
    Filing Date: March, 07 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: March, 06 2018



    Daily Technical Chart for (NASDAQ: LGND)

    Daily Technical Chart for (NASDAQ: LGND)

    Stay tuned for daily updates and more on (NASDAQ: LGND)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (NASDAQ: LGND)

    Do your DD and if you choose, be ready to go!


    The Research: All source information contained in this email is from the public sources mentioned below.



    Thank you

    DD Report



    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in LGND is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of LGND and does not buy, sell, or trade any shares of LGND. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: